ESTEVE to Expand U.S. Presence by Acquiring TerSera Therapeutics' Infusion Therapy Business

ESTEVE's Strategic Acquisition of TerSera's Infusion Therapy Unit

In a move that underscores its commitment to expanding its operations in the United States, ESTEVE, the Spanish pharmaceutical giant, has signed a significant agreement to acquire the Infusion Specialty Therapies Business Unit of TerSera Therapeutics LLC. This strategic acquisition, officially announced on January 13, 2026, will enable ESTEVE to enhance its portfolio with two highly specialized products and a dedicated team focusing on sales, marketing, and medical affairs.

The Infusion Specialty Therapies Unit includes two notable medications: Prialt® and Quzyttir®. Prialt® is particularly remarkable; it is the only non-opioid drug approved by the U.S. FDA for treating severe chronic pain in adult patients requiring intrathecal therapy. This medication is essential for those who cannot tolerate or who are resistant to other treatments, such as systemic analgesics and morphine. Currently, Prialt® is available in Europe through ESTEVE, emphasizing the firm's established foothold in the pharmaceutical landscape.

On the other hand, Quzyttir® is noteworthy as the first FDA-approved second-generation injectable H1 antihistamine, aimed at treating acute urticaria in patients aged six months and older. This product adds a valuable dimension to ESTEVE's offerings in the U.S. market.

With this transaction, ESTEVE will secure the global rights for Quzyttir® in all territories, excluding China, while also consolidating its worldwide rights for Prialt®. Staffan Schüberg, CEO of ESTEVE, expressed enthusiasm about the acquisition, noting that it aligns with the company's strategic vision of providing specialized solutions where there are significant unmet medical needs. He emphasized that integrating Quzyttir® into their portfolio, alongside expanding their market presence with Prialt®, not only strengthens their expertise in specialized therapies but also accelerates their growth trajectory in the U.S., the largest pharmaceutical market globally.

Edward Donovan, CEO of TerSera, remarked on the long-standing partnership with ESTEVE, particularly for Prialt® in Europe. He expressed confidence that ESTEVE is the ideal partner for the IST unit due to their shared goals and areas of expertise. This acquisition is expected to sustain the momentum that both companies have built with these medications, while allowing TerSera to refocus on core therapeutic areas such as oncology and rare diseases.

This acquisition is part of ESTEVE's broader strategy to solidify its presence in the United States, which began with the 2024 acquisition of a business specializing in rare and ultra-rare diseases in endocrinology and oncoendocrinology. The company continues to strengthen its specialized portfolio through the recent Authorization to Market of a biological product outside the U.S. that treats severe primary insulin-like growth factor deficiency in pediatric patients, alongside investigational treatments in the U.S., emphasizing their commitment to advancing therapeutic options.

The closing of this transaction is anticipated in the first quarter of 2026, contingent upon regulatory approvals. Perella Weinberg Partners is serving as the financial advisor to ESTEVE, with Arnold & Porter acting as legal counsel, while Leerink Partners functions in a similar advisory capacity for TerSera, with Kirkland & Ellis LLP providing legal guidance.

About ESTEVE

Founded in 1929 and headquartered in Barcelona, ESTEVE is a global pharmaceutical company committed to improving lives. With a strong international presence, the company markets specialized treatments that address important unmet medical needs across various therapeutic areas. Their CDMO services reflect their commitment to high-quality pharmaceutical production across multiple regions, including Spain, Mexico, China, and the United States.

About TerSera Therapeutics

Established in 2016, TerSera Therapeutics is known for its focus on oncology and rare diseases. The company focuses on unique therapies that significantly impact patient outcomes. Recognized as one of the Best Places to Work in 2025, TerSera continues to strive for excellence in the healthcare industry.

For more information about ESTEVE, visit esteve.com. For TerSera Therapeutics, check tersera.com.